Warning: The NCBI web site requires JavaScript to function. more...
The potential benefits of low-molecular-weight heparins in cancer patients.
Robert F.
J Hematol Oncol. 2010 Jan 14;3:3. Review.
Related citations
Low-molecular-weight heparin in cancer-associated thrombosis: treatment, secondary prevention, and survival.
Nishioka J, Goodin S.
J Oncol Pharm Pract. 2007 Jun;13(2):85-97. Review.
Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
Huo MH, Muntz J.
Clin Ther. 2009 Jun;31(6):1129-41. Review.
Impact of venous thromboembolism and anticoagulation on cancer and cancer survival.
Kuderer NM, Ortel TL, Francis CW.
J Clin Oncol. 2009 Oct 10;27(29):4902-11. Epub 2009 Sep 8. Review.
The role of low-molecular-weight heparins in the prevention and treatment of venous thromboembolism in cancer patients.
Lee AY.
Curr Opin Pulm Med. 2003 Sep;9(5):351-5. Review.
Thromboprophylaxis with low-molecular-weight heparin in medical patients with cancer.
Lyman GH.
Cancer. 2009 Dec 15;115(24):5637-50. Review.
Bemiparin in oncology.
Monreal Bosch M, Vignoli A, Lecumberri Villamediana R, Prandoni P.
Drugs. 2010 Dec 14;70 Suppl 2:35-42. doi: 10.2165/1158585-S0-000000000-00000. Review.
Low-molecular-weight heparin for thromboprophylaxis.
Camporese G, Bernardi E.
Curr Opin Pulm Med. 2009 Sep;15(5):443-54. Review.
Low molecular weight heparins in cancer. Management and prevention of venous thromboembolism in patients with malignancies.
ten Cate-Hoek AJ, Prins MH.
Thromb Res. 2008;122(5):584-98. Epub 2007 Nov 8. Review.
Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J; American College of Chest Physicians.
Chest. 2008 Jun;133(6 Suppl):844S-886S.
Anticoagulation therapy for prevention and treatment of venous thromboembolic events in cancer patients: a review of current guidelines.
Petersen LJ.
Cancer Treat Rev. 2009 Dec;35(8):754-64. Epub 2009 Sep 16. Review.
Low-molecular-weight heparins are superior to vitamin K antagonists for the long term treatment of venous thromboembolism in patients with cancer: a cochrane systematic review.
Akl EA, Barba M, Rohilla S, Terrenato I, Sperati F, Muti P, Schünemann HJ.
J Exp Clin Cancer Res. 2008 Jul 18;27:21. Review.
Managing cancer-related venous thromboembolic disease: low-molecular-weight heparins and beyond.
O'Connell CL, Liebman HA.
Expert Rev Hematol. 2008 Dec;1(2):175-82. Review. Erratum in: Expert Rev Hematol. 2009 Feb;2(1):110.
Are all low molecular weight heparins equivalent in the management of venous thromboembolism?
Fareed J, Jeske W, Fareed D, Clark M, Wahi R, Adiguzel C, Hoppensteadt D.
Clin Appl Thromb Hemost. 2008 Oct;14(4):385-92. Review.
Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis.
Gould MK, Dembitzer AD, Sanders GD, Garber AM.
Ann Intern Med. 1999 May 18;130(10):789-99.
Prevention of deep vein thrombosis in cancer patients.
Semin Thromb Hemost. 2007 Oct;33(7):699-706. Review.
Low molecular weight heparins as extended prophylaxis against recurrent thrombosis in cancer patients.
Engman CA, Zacharski LR.
J Natl Compr Canc Netw. 2008 Aug;6(7):637-45. Review.
Prevention of venous thromboembolism in hospitalized patients with cancer.
Francis CW.
J Clin Oncol. 2009 Oct 10;27(29):4874-80. Epub 2009 Aug 24. Review.
Low-molecular-weight heparins in the treatment of cancer-associated thrombosis: a new standard of care?
Burris HA 3rd.
Semin Oncol. 2006 Apr;33(2 Suppl 4):S3-16; quiz S41-2. Review.
Prevention of venous thromboembolism in cancer using low-molecular-weight heparins.
Kakkar AK, Williamson RC.
Haemostasis. 1997;27 Suppl 1:32-7. Review.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on